Robert A. Copeland, President of Research and CSO at Epizyme, Inc. (EPZM), sold 8,370 shares at $15.58 ($130K) on 2016-01-04, disclosed to the SEC on 2016-01-04.
Open-market sale of $130k EPZM by President of Research and CSO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.58 | 292 | $5K | 3.5% |
| 2 | $15.58 | 3,893 | $61K | 46.5% |
| 3 | $15.58 | 292 | $5K | 3.5% |
| 4 | $15.58 | 3,893 | $61K | 46.5% |
| Total | $15.58 avg | 8,370 | $130K | 100% |
| Filing → |
| EPZM | SELL | 2017-04-05 | $41K | — | Filing → |
| EPZM | SELL | 2016-08-03 | $83K | — | Filing → |
| EPZM | SELL | 2016-07-07 | $80K | — | Filing → |